Clinical Trial Update: CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants [Phase 3]

View source ↗

Summary

Phase 3 trial (CLEAR Study) evaluating CellCept (mycophenolate mofetil) in kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED